PDCD1 and sarcoma: Generally, limited evidence exists on the activity of ICI in sarcoma with low clinical activity of anti-PD1 alone in most sarcoma subtypes suggesting that blocking the PD1 negative signaling alone is not sufficient to adequately reactivate the exhausted endogenous antitumor effector T cells in these patients [35].